Analyst Ratings for Aktis Oncology (AKTS)
AKTS Rating Summary
AKTS Price Target Summary
- Highest: $40.00 (Raymond James)
- Lowest: $33.00 (JPMorgan)
- Average: $35.29
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$35.29 (+35.8%)
* Over Last 12-Mos
Rating Score: 7.9 / 10
Percentile Rank: 82%
Rating Score: 7.9 / 10
Percentile Rank: 82%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/19/2026 | Wedbush | David Nierengarten | New Coverage | Outperform (N/A) |
35.00 (N/A) |
25.00 (25.99) |
3.96% | Details |
| 8/18/2026 | BMO Capital | David Lebowitz | New Coverage | Outperform (N/A) |
37.00 (N/A) |
24.72 (25.99) |
5.14% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
